2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1964

Biomarkers in Temporal Artery Biopsies and Sera of Patients with Giant Cell Arteritis
Abstract Number: 1965

T Cell Activation, Proliferation and Differentiation Markers Lack Diagnostic Accuracy for Detecting Active GCA and PMR
Abstract Number: 1966

Active PMR and GCA Is Associated with Changes in Monocyte Subset Composition
Abstract Number: 1967

Deregulation of Interleukin-22 Pathway in Giant Cell Arteritis
Abstract Number: 1968

Distinct Distribution Patterns of Large Vessel Vasculitis Assessed with 18f-FDG PET/CT: Evidence from Principal Component and Cluster Analyses
Abstract Number: 1969

Can We Predict the Relapse of Giant Cell Arteritis?
Abstract Number: 1970

Incidence and Predictors of Thoracic Aortic Damage in Biopsy-Proven Giant Cell Arteritis: A Single-Institution Cohort Study
Abstract Number: 1971

Healthcare Utilization and Direct Medical Costs of Giant Cell Arteritis
Abstract Number: 1972

Cardiovascular and Cerebrovascular Disease and Social Deprivation in Patients with Giant Cell Arteritis
Abstract Number: 1973

Giant Cell Arteritis and Risk of Cerebrovascular Accident: A Systematic Review and Meta-Analysis
Abstract Number: 1974

Do Patients with Giant Cell Arteritis Meet the 2011 United Kingdom Department of Health Guidance on Physical Activity?
Abstract Number: 1975

Risk of Mortality of Patients with Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Abstract Number: 1976

Corticosteroid Therapy in Giant Cell Arteritis, Predictors for Long-Term Remission
Abstract Number: 1977

Long-Term Survival of Methotrexate in Giant Cell Arteritis Patients in Clinical Practice
Abstract Number: 1978

Tocilizumab in Refractory Large Vessel Vasculitis with Aorta Involvement. Study on 10 Patients Evaluated By Positron Emission Tomoghraphy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].